

Bibliography – Nasal PNIF

1. Badia Lydia, Lund Valerie. Topical Corticosteroids in Nasal Polyposis. *Drugs* 2001; 61 (5).
2. Bittera I, Kadocsa E, Elek A, Tegzes E, Menczel L, Tekulics P. Comparison of budesonide and fluticasone nasal sprays in the treatment of children with allergic rhinitis. *Allergy* 2000, Supplement 63, Volume 55, Abstract no. 649, 2000.
3. Briscoe M.P., Day J.H., Rafeiro E., Pettersson E. Akerlund A. #1134 Onset of Action of Intranasal Budesonide (Rhinocort® Aqua) in Seasonal Allergic Rhinitis (SAR) Studied in a Controlled Exposure Model.
4. Cho S. MD; Hauser R., MD,ScD, MPH; Christiani D., MD, MPH, FCCP. Reproducibility of Nasal Peak Inspiratory Flow Among Healthy Adults. *Chest*/112/6/ December 1997.
5. Da Graça Castel-Branco M, Bende M, Carrillo T, Vòna I, Arheden L. Budesonide Aqueous Nasal Spray (BANS) Compared to Mometasone Furoate (MF) in Patients with Perennial Allergic Rhinitis. *Allergy* 2000, Supplement 63, Volume 55, Abstract 665, 2000.
6. Da Graça Castel-Branco M, Ståhl E, Svensson K, Bende M, Carrillo T, Vòna I, Arheden L. Health-Related Quality of Life, Assessed by a Generic Questionnaire (SF-36), Improved in Budesonide Aqueous Nasal Spray Treated Patients with Perennial Allergic Rhinitis. *Allergy* 2000, Supplement 63, Volume 55, Abstract 671, 2000.
7. Day JH et al. Onset of activity of Rhinocort using the Youlton. *J. Allergy & Clin. Immunol* 2000 105:489-94.
8. Day JH, Briscoe MP, Rafeiro E, Ellis AK, Pettersson E, Akerlund A. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. *J Allergy Clin Immunol* 2000 Mar; 105(3):489-94.
9. Dempsey O.J, Wilson A.M, Sims E.J, Lipworth B.J. A Comparison of Once Daily Topical Budesonide (BUD) and Oral Montelukast (MON) in Seasonal Allergic Rhinitis (SAR) and Asthma. *European Respiratory Journal*, Volume 14, Supplement 30, October 1999.
10. Dessanges J.F., Test de provocation nasale (TPN). Fiche Technique no. 14.
11. Didour M.D, Jurkov I.V, Sinitcina T.M, Pravosudov V.P, Titova O.N, Suchneva L.V. Efficacy of nasal force inspiratory maneuver in asthmatic patients. *The European Respiratory Society* 2000, Italy ERJ Volume 16, S31, 1s-658s.
12. Fokkens W.J, Cserhati E, dos Santos JML, Hosszu Z. Efficacy of Budesonide Aqueous Nasal Spray (Rhinocort® Aqua) in Children with Perennial Allergic Rhinitis. *AAAAI*, 56th Annual Meeting. Abstract No 1145, 1999.
13. Fokkens W, Pinto R, Cserháti E, Praca F, van Zanten M, Schade A, Simon G, Pettersson E. Budesonide Aqueous Nasal Spray in Children with Perennial Allergic Rhinitis. *Allergy* 2000, Supplement 63, Volume 55, Abstract 131, 2000.

14. Ghaem A., Dessanges J.P., Lockhart A., Martineaud J.P. Exploration Par Rhinomanometrie des maladies atteints d'allergie respiratoire. Bull. Eur. Physiopathol. Respir 1986, 22, 443-449.
15. Gleeson M.J, Youlten L.J.F, Shelton D.M, Siodlak M.Z, Eiser N.M and Wengraf C. Assessment of Nasal Airway Patency: A comparison of four methods. Clin. Otolaryngol. 1986, 11, 99-107.
16. Hallen H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin. Exp Allergy 1997 May 27(5): 552-8.
17. Hellgren J, Jarlstedt J, Dimberg L, Torén K, Karlsson G. A Study of Some Current Methods for Assessment of Nasal Obstruction. European Respiratory Journal 1996, Vol 9, S23 (0203), 18s.
18. Holmberg K, MD, PhD, Juliusson S MD, PhD, Balder, Smith D L, Richards DH, Karlsson G MD, PhD. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Annals of Allergy, Asthma & Immunology Vol. 78, Number 3, March 1997.
19. Holmström M., Scadding G.K, Lund V.J and Darby Y.C. Assessment of Nasal Obstruction. A comparison between rhinomanometry and nasal Inspiratory peak flow. Rhinology, 28, 191-196, 1990.
20. Holmstrom M. Clinical performance of fluticasone propionate nasal drops. Allergy 1999;54 Suppl 53:21-5.
21. Jankowski R. MD; Schrewelius, DDS; Bonfils P., MD; Saban Y.MD; Gilain L, MD; Prades J-M., MD; Strunski V.,MD. Efficacy and Tolerability of Budesonide Aqueous Nasal Spray Treatment in Patients with Nasal Polyps.
22. Jordana G, Dolovich J, Briscoe MP, Day JH, Drouin MA, Gold M, Stepner N, Yang W. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1996 Feb. 97 (2): 588-95.
23. Keith P., Nieminen J.,Hollingworth K., Dolovich J. Efficacy and tolerability of flicasonone propionate nasal drops 400mcg once daily compared with placebo for the treatment of bilateral polyposis in adults. Clinical and Experimental Allergy, 2000, volume 30, pages 1460-1468.
24. Landwehr L.P., Vandewalker M.L., Stricker W.E. A Pilot Study of the Effect of Topical Nasal Peak Inspiratory Flow Rate in Allergic Rhinitis. Poster Annual Meeting-American College of Allergy, Asthma & Immunology.
25. Larsen K., Oxhoj H., Grontved A., Kristensen S. Peak flow nasal patency indices in patients operated for nasal obstruction, European Archives of Otorhinolaryngol (1990) 248: 21-24.
26. Lund Valerie J. MD; Flood Joanne, RSN; Andrew P Sykes, BSc; David H. Richards, BSc. Effect of Fluticasone in Severe Polyposis. Archives of Otolaryngology – Head & Neck Surgery May 1998 Volume 124.

27. Mackay I.S., Durham S.R. Perennial rhinitis. *BMJ* 1998;316:917 (21 March).
28. Mastalerz L, Milewski M, Duplaga M, Nizankowska E, Szczeklik A. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin induced asthma. *Allergy* 1997 Sep;52(9):895-900.
29. Penttilä M., Poulsen P., Hollingworth K., Holmström M., Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 mcg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomised study in adult patients. *Clinical and Experimental Allergy*, 2000, Volume 30, Pages 94-102.
30. Prescott C.A.J, Prescott K.E. Peak Nasal Inspiratory flow measurement: an investigation in children. *International Journal of Pediatric Otorhinolaryngology* 32 (1995) 137-141.
31. Rowe-Jones Julian M. FRCS, Mackay Ian s., Management of nasal polyps. *Current Opinion in Otolaryngology & Head and Neck Surgery* 1998, 6:41-46.
32. Taylor MA, Reilly D Llewellyn-Jones RH, McSharry C, Aitchison TC. Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial series. *BMJ* 2000 Aug 19-26;321(7259):471-6.
33. Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. *J Allergy Clin Immunol* 1999 Jun; 103(6):1025-30.
34. Wihl J-A, Malm I., Rhinomanometry and nasal peak expiratory an inspiratory flow rate. *Annals of Allergy*, Volume 61, July 1988.
35. Pearce L. Revisiting Inhalers – Selecting an Inhaler *Practice Nursing* 2002, Volume 13, No 12, p561.
36. Wilson A, Sims E, Coutie W, Lipworth B. Domiciliary Nasal Flow Is A Better Marker of Treatment Response Than Rhinomanometry or Acoustic Rhinometry in Patients With Allergic Rhinitis and Asthma. AAAAI 56th Annual Meeting. Abstract No 609, 1999.
- 37 Wilson A.M, Dempsey O.J, Sims E.J, Lipworth B.J. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2000 Aug; 85 (2):111-4.
38. Wilson A.M, Orr L.C, Sims E.J, Lipworth B.J. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. *Clinical and Experimental Allergy*, 2001, Volume 31, pages 61-68.
39. Wilson A.M, Dempsey O.J, Sims E.J, Lipworth B.J. A comparison of topical budesonide and oral montelukast in allergic rhinitis and asthma. *Clin Exp Allergy* 2001 Apr; 31 (4):616-24.

40. Wilson A.M, Sims E.J, Orr L.C., Coutie W.J., White P.S., Gardiner Q.I. Effects of topical corticosteroid and combined mediator.
41. Wilson A.M., Orr L.C., Coutie W.J.R., Sims E.J., Lipworth B.J. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. *Clin Exp All* 2002; 32:126-132.
42. Wilson AM, White PS, Gardiner Q, Nassif R, Lipworth BJ. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. *Rhinology* 2001 Sep;39 (3): 142-6.
43. Wilson AM, Sims EJ, Orr LC, Coutie WJ, White PS, Gardiner Q, Lipworth BJ. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2001 Oct;87 (4);344-9.
44. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol*. 2000 Aug; 85(2):87-8.
45. Youlton L.J.F., Nasal Airway Patency Measurement in the Assessment of Rhinitis Therapy.
46. Youlton L.J.F The Peak Nasal Inspiratory Flow Meter: A new instrument for the assessment of the response to immunotherapy in seasonal allergic rhinitis. *Allergol Immunopathol*, 1980 8 (344).
47. Zoest Van J.G., Weij van der A.M., Duiverman E.J., Akerlund A, Kouwenberg JM. Nasal peak inspiratory flow through turbuhaler in children with symptomatic rhinitis and in healthy children. *Pediatric Allergy Immunol* 2000 Nov; 11(4): 256-9.